REGENXBIO Inc.: stock overview

RGNXNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$7.64

November 13, 2026Market cap $505M

DCF calculator

What Ploutos Investor adds for REGENXBIO

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 13 fiscal years, from 2013
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

In short

REGENXBIO had revenue of $154M over the last 12 months and a net loss of $175M. Revenue grew by 2.0% a year on average over the last 5 years. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$505M
66.12M shares
P/E
–
Revenue, 12 months
$154M
+2.0% a year over 5 years
Net margin
-113.9%
2025: -113.8%, above 13% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+37.4% a year over 2 years

Fiscal years in figures

RGNX's revenue, profit, cash flow and dividend with each year-end price, from 2013 to 2022, 10 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $743M
$505M
Enterprise value 
–
P/E 
–
EV / EBIT 
–
EV / Revenue 
–
P/B 3-year median: 2.6
3.4
FCF yield 3-year median: -28.6%
–
Earnings yield 3-year median: -33.5%
–

Profitability

Operating margin 
-95.7%
Net margin 3-year median: -272.5%
-113.9%
ROIC 
-115.2%
ROIC, 5-year average 
-40.7%
ROE 
-173.5%

Growth

Revenue, yearly change 
+104.5%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
+2.0%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$251M
Total debt 
–
Net cash 
–
Net debt / EBITDA 
–
Interest cover 
-4.1x
Current ratio 
4.74

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+3.1%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Operating margin

-94.6%

Above 18% of the 285 companies in its industry, and 4% of all.

Net margin

-113.8%

Above 13% of the 302 companies in its industry, and 3% of all.

ROE

-188.7%

Above 4% of the 267 companies in its industry, and 2% of all.

ROA

-42.8%

Above 13% of the 313 companies in its industry, and 4% of all.

Revenue growth

104.5%

Above 93% of the 292 companies in its industry, and 98% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
REGENXBIO Inc.
CIK
1590877
Exchange
NASDAQ
Industry (SIC)
2836 · Biological Products, (No Diagnostic Substances)
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
66.12M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do REGENXBIO's filings show?

These are REGENXBIO's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about RGNX

Didn't find what you were looking for?

Ask us
What is RGNX's market cap?

REGENXBIO Inc.'s market cap is $505M, at a price of $7.64 on November 13, 2026 and 66.12M shares.

How much revenue does RGNX have?

REGENXBIO had revenue of $154M over the last 12 months. Over the last 5 years it changed by +2.0% a year on average.

Does RGNX pay a dividend?

No. REGENXBIO paid no regular dividend over the last 12 months.

Where do the figures come from?

From REGENXBIO Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.